Draxis Extends Maintenance Shutdown of Contract Manufacturing Facility

Draxis Pharma, the pharmaceutical contract manufacturing division of Draxis Health Inc. (Mississauga, ON, Canada), has extended its scheduled summer maintenance shutdown of its sterile and lyophilized product manufacturing areas. The shutdown was extended to allow the company to replace a major electrical panel and a pump assembly, and to perform "further cleaning and decontamination of the sterile production area," according to a company statement. The shutdown, originally scheduled to last two to three weeks, is now expected to last five to seven weeks. Company officials declined to provide additional details until they issue a follow-up announcement about the resumption of production.

–Laura Bush